Predictors of Pulmonary Complications After Rib Fractures: Systematic Review and Meta-Analyses.

J Surg ResSep 25, 2026 (epub)

Sabastian Turyakira, Enock Mukiibi, Samuel Oledo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined multivariable-adjusted predictors of pulmonary complications in adults with blunt rib fractures. Twelve studies involving 72,380 patients from nine countries were included. Displaced rib fractures had the strongest pooled association with complications (adjusted OR 3.32, 95% CI 1.78-6.19; I² = 0%). Male sex was also associated (OR 2.02, 95% CI 1.17-3.48; I² = 0%). Greater fracture burden showed an exploratory association (OR 2.10, 95% CI 1.20-3.67), but varied thresholds and outcomes limit its interpretation as a single clinical effect.

Key findings

  • Displaced rib fractures were associated with pulmonary complications: pooled adjusted OR 3.32, 95% CI 1.78-6.19; I² = 0%.
  • Male sex was independently associated with complications (OR 2.02, 95% CI 1.17-3.48; I² = 0%).
  • Fracture burden had an exploratory pooled association (OR 2.10, 95% CI 1.20-3.67; I² = 25%), with heterogeneous thresholds and outcomes.
  • Narrative synthesis also identified age ≥65 y, chronic obstructive pulmonary disease, upper or midline fractures, and bilateral involvement as higher-risk features.

Why it matters

Pulmonary complications are a major source of morbidity, mortality, and resource use after rib fractures. Identifying features associated with higher risk may help clinicians structure early assessment and monitoring. The pooled estimates distinguish the comparatively consistent association with displacement from the more uncertain fracture-burden estimate, while the narrative findings add patient and injury characteristics for consideration.

What to keep in mind

The fracture-burden estimate combined heterogeneous thresholds and a delayed-outcome estimate, so it is exploratory. The review also notes that publication-bias tests are underpowered with few studies and calls for prospective studies using standardized outcomes and validated prediction models.

Source

Published in J Surg Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.